Tapering Benzodiazepines

Consider the following principles in designing individualized benzodiazepine tapering schedules

- Go slowly and gradually¹
 - Reduction of ~ 25% of the initial dose every 2 weeks until the lowest available dose is reached^{2,3,4,5} OR
 - Decrease total daily dose by 25% the 1st week, another 25% the 2nd week, then 10% a week until discontinuation²
 - Moderate reductions at higher doses and smaller reductions at lower doses¹
 - The specific dose reductions would vary as a function of patients' readiness to discontinue and the presence or absence of withdrawal symptoms⁴
 - Withdrawal symptoms rebound anxiety, restlessness, tremor, sweating, agitation, insomnia, or seizures (particularly when benzos are used > 8 weeks)^{2,4,5}
 - Onset of withdrawal symptoms: 1 to 2 days for benzos with short half-lives, 3 to 7 days for longer half-lives²
 - Stabilization: Single benzodiazepine (if using >1 benzodiazepine)^{4.5}
 - Introduction of an increasing number of drug-free nights. Scheduled hypnotic use rather than prn use⁴
 - Monitor for withdrawal symptoms or symptom exacerbation. If either occurs, consider maintaining the current benzodiazepine dose or increasing the dose for 1 to 2 weeks or longer, if necessary, then continue to taper at a slower rate²
 - o Aggressively treat psychopathology while still on benzodiazepine

- Consider use of cognitive therapy and adjunctive agents to improve success rates (eg. imipramine, trazodone, carbamazepine, & valproate)^{3,6}
- In patients who have tried but failed to withdraw previously, a 6-month schedule may be necessary as shown below³

Week	Dosage (mg/day)	
1	Starting dose (e.g. diazepam 15 mg/d or equivalent)	
2	15 down to 11	
4	11 down to 8.5	
6	8.5 down to 6	
8	6 down to 4.75	
10	4.75 down to 3.5	
12	3.5 down to 2.5	
14	2.5 down to 2	
16	2 down to 1.5	
18	1.5 down to 1	
20	1 down to 0.75	
22	0.75 down to 0.5	
24	0.5 down to 0.25	
26	0.25 down to 0 (stop)	

Note: Diazepam formulations for dosage tapering

- o Solution 1 mg/mL (5 mL, 500 mL)
- o Tablets: 2 mg, 5 mg, 10 mg

- Recommended taper when benzodiazepine use > 1 year
 - Reduce dose no faster than 10% a week, until reach 10 mg diazepam equivalent. Maintain reduced dose for several months before final taper
 - Decrease 10% every 1 to 2 weeks. When 20% of the dosage remains, begin a 5% dose reduction every 2 to 4 weeks²

Recommended durations for tapering benzodiazepines²

Duration of use	Recommended taper Length	Comments
<6 to 8 weeks	Taper may not be required	Depending on clinical judgment and patient stability/preference, consider implementing a taper, particularly if using a high-dose benzodiazepine or an agent with a short or intermediate half-life, such as alprazolam or triazolam
8 weeks to 6 months	Slowly over 2 to 3 weeks	Go slower during latter half of taper. Tapering will reduce, not eliminate, withdrawal symptoms. Patients should avoid alcohol and stimulants during benzodiazepine withdrawal
6 months to 1 year	Slowly over 4 to 8 weeks	
>1 year	Slowly over 2 to 4 months	

References

- 1. Ahmed, Mariyam, Henny A. Westra, and Sherry H. Stewart. "A self-help handout for benzodiazepine discontinuation using Cognitive Behavioral Therapy." *Cognitive and Behavioral Practice* 15.3 (2008): 317-324.
- 2. Bostwick JR, Casher MI, Yasugi S. Benzodiazepines: a versatile clinical tool. *Current Psychiatry* 2012;11(4):55-64.
- 3. Lader, Malcolm, Andre Tylee, and John Donoghue. "Withdrawing benzodiazepines in primary care." *CNS drugs* 23.1 (2009): 19-34.
- 4. Morin, Charles M., et al. "Randomized clinical trial of supervised tapering and cognitive behavior therapy to facilitate benzodiazepine discontinuation in older adults with chronic insomnia." *American Journal of Psychiatry* 161.2 (2004): 332-342.
- 5. Morin, Charles M., et al. "Long-term outcome after discontinuation of benzodiazepines for insomnia: a survival analysis of relapse." *Behaviour research and therapy* 43.1 (2005): 1-14.
- 6. Rickels, Karl, et al. "Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy." *American Journal of Psychiatry* 157.12 (2000): 1973-1979.
- 7. Shader, Richard I., and David J. Greenblatt. "Use of benzodiazepines in anxiety disorders." *New England Journal of Medicine* 328.19 (1993): 1398-1405.